MLYS earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -13.18. Updated 2026-07-23.
Mineralys Therapeutics (MLYS) Research Hub
Mineralys Therapeutics (MLYS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 28.2 USD (-7.54%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -13.18, market cap 1.79B. This hub links to the full technical, earnings and options research available for MLYS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 28.2 USD (-7.54%) |
| 52-week range | 23.4 USD – 31.99 USD |
| Trend regime | Range |
| 14-day RSI | 53.1 (Neutral) |
| Trailing P/E | -13.18 |
| Market cap | 1.79B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for MLYS
Covered Call on MLYS: how it works, illustrative setup around the real 28.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MLYS: how it works, illustrative setup around the real 28.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MLYS: how it works, illustrative setup around the real 28.2 USD price, max profit/loss, breakeven and when to use it. Educational.
MLYS technical analysis: range, last 28.2 USD, RSI 53.1, 52w range 23.4 USD–31.99 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MLYS in?
Mineralys Therapeutics (MLYS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MLYS in an uptrend or downtrend?
As of 2026-09-11, MLYS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MLYS's trailing P/E ratio?
MLYS's trailing P/E is -13.18, with a market cap of 1.79B. See the earnings research page for full valuation detail.
When does MLYS next report earnings?
MLYS is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.57 USD.